Cholangiocarcinoma Market Report 2026

Cholangiocarcinoma Market Overview

• Cholangiocarcinoma market size has reached to $0.62 billion in 2025 • Expected to grow to $1.14 billion in 2030 at a compound annual growth rate (CAGR) of 12.8% • Growth Driver: Rising Liver Disease Incidence Drives The Growth Of The Market • Market Trend: Advancements In Targeted Therapies With FGFR Inhibitors In The Treatment • North America was the largest region in 2025.

What Is Covered Under Cholangiocarcinoma Market?

Cholangiocarcinoma is a malignant tumor that arises from the bile ducts, which carry bile from the liver to the small intestine. It is characterized by uncontrolled growth of abnormal cells, leading to bile duct obstruction and liver dysfunction. Symptoms often include jaundice, abdominal pain, weight loss, and fatigue. Early diagnosis and treatment are crucial for better prognosis and management. The main cancer types of cholangiocarcinoma are intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma. Intrahepatic cholangiocarcinoma (ICC) is a rare, aggressive liver cancer that originates in the bile ducts within the liver. Treatment options for cholangiocarcinoma vary based on different product types, including capecitabine, 5-fluorouracil, oxaliplatin, gemcitabine, and cisplatin. Therapies encompass targeted drug therapy, chemotherapy, and immunotherapy, administered through oral, subcutaneous, or intravenous routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and e-commerce platforms.

What Is The Cholangiocarcinoma Market Growth Forecast?

The cholangiocarcinoma market size is expected to see rapid growth in the next few years. It will grow to $1.14 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing development of targeted oncology drugs, rising use of personalized medicine approaches, expansion of clinical trials in rare cancers, growing investment in oncology research, increasing focus on early-stage diagnosis. Major trends in the forecast period include increasing adoption of targeted drug therapies, rising use of combination chemotherapy regimens, growing focus on precision oncology, expansion of immunotherapy research, enhanced emphasis on early diagnosis.

Global Cholangiocarcinoma Market Segmentation

1) By Cancer: Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma 2) By Product: Capecitabine, 5-Fluorouracil, Oxaliplatin, Gemcitabine, Cisplatin 3) By Therapy: Targeted Drug Therapy, Chemotherapy, Immunotherapy 4) By Route Of Administration: Oral, Subcutaneous, Intravenous 5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, E-Commerce Subsegments: 1) By Intrahepatic Cholangiocarcinoma: Peripheral Intrahepatic Cholangiocarcinoma, Mass-Forming Intrahepatic Cholangiocarcinoma 2) By Extrahepatic Cholangiocarcinoma: Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma

What Is The Driver Of The Cholangiocarcinoma Market?

The increasing liver disease incidence is expected to propel the growth of the cholangiocarcinoma market going forward. Liver disease refers to any condition that impairs the normal function or structure of the liver, including diseases such as hepatitis, cirrhosis, fatty liver disease, and liver cancer. Liver disease incidence is rising due to increasing risk factors like obesity, diabetes, alcohol consumption, and viral hepatitis infections. Liver disease, particularly chronic inflammation and cirrhosis, increases the risk of cholangiocarcinoma by promoting bile duct damage and malignant cell transformation. For instance, in December 2024, according to the Office for Health Improvement and Disparities, a UK-based government agency, in 2023, premature deaths from alcoholic liver disease rose 3.6% to 5,984, up from 5,776 in 2022. Therefore, increasing liver disease incidence is driving growth in the cholangiocarcinoma industry.

Key Players In The Global Cholangiocarcinoma Market

Major companies operating in the cholangiocarcinoma market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boston Scientific Corporation, Servier Laboratories, Incyte Corporation, Exelixis Inc., Hutchison China MediTech Limited, Zymeworks Inc., Agios Pharmaceuticals Inc., RenovoRx Inc., Specialised Therapeutics Pty Ltd, Ascletis Pharma Inc., Tiziana Life Sciences Ltd., Taiho Pharmaceutical Co. Ltd.

Global Cholangiocarcinoma Market Trends and Insights

Major companies operating in the cholangiocarcinoma market are focusing on developing novel treatments, such as targeted therapies, to improve treatment outcomes for patients. Targeted therapies are treatments designed to focus on specific genes, proteins, or molecules that help cancer cells grow. These therapies work by blocking the processes that allow cancer to grow, aiming to stop tumor growth, reduce side effects, and improve treatment results. For instance, in August 2023, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched LYTGOBI (futibatinib), an FGFR inhibitor, for the treatment of unresectable biliary tract cancer with FGFR2 gene fusions. It is designed to selectively and irreversibly inhibit FGFR signaling, helping to slow tumor growth and improve outcomes in patients with cholangiocarcinoma (iCCA) that has progressed after chemotherapy.

What Are Latest Mergers And Acquisitions In The Cholangiocarcinoma Market?

In July 2023, Lucence, a US-based precision health company, partnered with Innovent Biologics Inc. to advance bile duct cancer diagnostics. Under this agreement, Innovent will sponsor Lucence’s LiquidMARK Bile Duct test for eligible patients in Hong Kong, improving diagnostic accuracy and treatment options. Innovent Biologics Inc. is a China-based biotechnology company focused on developing innovative therapies, including treatments for cholangiocarcinoma.

Regional Outlook

North America was the largest region in the cholangiocarcinoma market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cholangiocarcinoma Market?

The cholangiocarcinoma market consists of revenues earned by entities by providing services such as diagnostic testing and imaging, surgical services, and supportive treatments to manage symptoms and improve patient outcomes. The market value includes the value of related goods sold by the service provider or included within the service offering. The cholangiocarcinoma market also includes sales of advanced imaging systems, molecular diagnostic tests, and drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cholangiocarcinoma Market Report 2026?

The cholangiocarcinoma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cholangiocarcinoma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.